Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Pulmonary Infections pipeline constitutes 10+ key companies continuously working towards developing 15+ Chronic Pulmonary Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
' Chronic Pulmonary Infections Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Pulmonary Infections Market.
The Chronic Pulmonary Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Chronic Pulmonary Infections Pipeline Report:
Companies across the globe are diligently working toward developing novel Chronic Pulmonary Infections treatment therapies with a considerable amount of success over the years.
Chronic Pulmonary Infections companies working in the treatment market are Armata Pharmaceuticals, BiomX, Inc., Respirion Pharmaceuticals, Chiesi Farmaceutici S.p.A., Incyte Corporation, American Health Research, Temple University, Altesa Biosciences, Genentech, Inc., and others, are developing therapies for the Chronic Pulmonary Infections treatment
Emerging Chronic Pulmonary Infections therapies in the different phases of clinical trials are- AP-PA02, BX004-A, RSP-1502, CHF6001, itacitinib, Guafenesin tablets, Quercetin, Vapendavir, GDC-6599, and others are expected to have a significant impact on the Chronic Pulmonary Infections market in the coming years.
In December 2024, Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a biotechnology company dedicated to developing high-purity, pathogen-specific bacteriophage therapies for chronic pulmonary diseases and antibiotic-resistant bacterial infections, has announced promising topline results from its Phase 2 "Tailwind" trial. The trial assessed the efficacy of AP-PA02, an innovative inhaled multi-phage therapeutic designed to treat chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections in patients with non-cystic fibrosis bronchiectasis (NCFB).
In May 2024, Insmed's stock price surged over 100% following the announcement that their leading pipeline candidate, brensocatib, achieved success in a Phase III trial. The much-anticipated ASPEN trial (NCT04594369) was an international, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.
In May 2024, Pfizer Inc. (NYSE: PFE) has released extended follow-up results from the Phase 3 CROWN trial, which compared LORBRENA® (lorlatinib), a third-generation ALK inhibitor, to XALKORI® (crizotinib) in patients with previously untreated, ALK-positive advanced non-small cell lung cancer (NSCLC). After a median follow-up of five years, the median progression-free survival (PFS) for LORBRENA, as assessed by investigators, was not reached. The observed Hazard Ratio (HR) was 0.19 (95% Confidence Interval [CI], 0.13-0.27), indicating an 81% reduction in disease progression or death compared to XALKORI.
Chronic Pulmonary Infections Overview
Chronic pulmonary infections refer to persistent or long-lasting infections affecting the respiratory system, particularly the lungs. These infections can be caused by various pathogens such as bacteria, viruses, fungi, or parasites. Chronic pulmonary infections are characterized by their prolonged duration and can lead to significant respiratory symptoms and complications if not properly managed.
Emerging Chronic Pulmonary Infections Drugs Under Different Phases of Clinical Development Include:
AP-PA02: Armata Pharmaceuticals
BX004-A: BiomX, Inc.
RSP-1502: Respirion Pharmaceuticals
CHF6001: Chiesi Farmaceutici S.p.A.
itacitinib: Incyte Corporation
Guafenesin tablets: American Health Research
Quercetin: Temple University
Vapendavir: Altesa Biosciences
GDC-6599: Genentech, Inc.
Chronic Pulmonary Infections Route of Administration
Chronic Pulmonary Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intravenous
Subcutaneous
Oral
Intramuscular
Chronic Pulmonary Infections Molecule Type
Chronic Pulmonary Infections Products have been categorized under various Molecule types, such as
Monoclonal antibody
Small molecule
Peptide
Chronic Pulmonary Infections Pipeline Therapeutics Assessment
Chronic Pulmonary Infections Assessment by Product Type
Chronic Pulmonary Infections By Stage and Product Type
Chronic Pulmonary Infections Assessment by Route of Administration
Chronic Pulmonary Infections By Stage and Route of Administration
Chronic Pulmonary Infections Assessment by Molecule Type
Chronic Pulmonary Infections by Stage and Molecule Type
DelveInsight's Chronic Pulmonary Infections Report covers around 15+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Chronic Pulmonary Infections product details are provided in the report. Download the Chronic Pulmonary Infections pipeline report to learn more about the emerging Chronic Pulmonary Infections therapies
Some of the key companies in the Chronic Pulmonary Infections Therapeutics Market include:
Key companies developing therapies for Chronic Pulmonary Infections are - Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim International Gmbh, Teva Pharmaceutical Industries Ltd, Sanofi, Mylan Pharmaceuticals, Sun Pharmaceutical, and others.
Chronic Pulmonary Infections Pipeline Analysis:
The Chronic Pulmonary Infections pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Pulmonary Infections with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Pulmonary Infections Treatment.
Chronic Pulmonary Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Pulmonary Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Pulmonary Infections market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Chronic Pulmonary Infections Pipeline Market Drivers
Increasing Prevalence, Unmet Medical Needs, Advancements in Biotechnology, Government Initiatives, Growing Healthcare Expenditure, are some of the important factors that are fueling the Chronic Pulmonary Infections Market.
Chronic Pulmonary Infections Pipeline Market Barriers
However, Complexity in Diagnosis, Regulatory Hurdles, High Development Costs, Antibiotic Resistance, Limited Awareness, and other factors are creating obstacles in the Chronic Pulmonary Infections Market growth.
Scope of Chronic Pulmonary Infections Pipeline Drug Insight
Coverage: Global
Key Chronic Pulmonary Infections Companies: Armata Pharmaceuticals, BiomX, Inc., Respirion Pharmaceuticals, Chiesi Farmaceutici S.p.A., Incyte Corporation, American Health Research, Temple University, Altesa Biosciences, Genentech, Inc., and others
Key Chronic Pulmonary Infections Therapies: AP-PA02, BX004-A, RSP-1502, CHF6001, itacitinib, Guafenesin tablets, Quercetin, Vapendavir, GDC-6599, and others
Chronic Pulmonary Infections Therapeutic Assessment: Chronic Pulmonary Infections current marketed and Chronic Pulmonary Infections emerging therapies
Chronic Pulmonary Infections Market Dynamics: Chronic Pulmonary Infections market drivers and Chronic Pulmonary Infections market barriers
Table of Contents
1. Chronic Pulmonary Infections Report Introduction
2. Chronic Pulmonary Infections Executive Summary
3. Chronic Pulmonary Infections Overview
4. Chronic Pulmonary Infections- Analytical Perspective In-depth Commercial Assessment
5. Chronic Pulmonary Infections Pipeline Therapeutics
6. Chronic Pulmonary Infections Late Stage Products (Phase II/III)
7. Chronic Pulmonary Infections Mid Stage Products (Phase II)
8. Chronic Pulmonary Infections Early Stage Products (Phase I)
9. Chronic Pulmonary Infections Preclinical Stage Products
10. Chronic Pulmonary Infections Therapeutics Assessment
11. Chronic Pulmonary Infections Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Chronic Pulmonary Infections Key Companies
14. Chronic Pulmonary Infections Key Products
15. Chronic Pulmonary Infections Unmet Needs
16 . Chronic Pulmonary Infections Market Drivers and Barriers
17. Chronic Pulmonary Infections Future Perspectives and Conclusion
18. Chronic Pulmonary Infections Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
20 minutes ago
- Winnipeg Free Press
House will vote on Trump's request to cut funding for NPR, PBS and foreign aid
WASHINGTON (AP) — House Republicans are moving to cut about $9.4 billion in spending already approved by Congress as President Donald Trump's administration looks to follow through on work by the Department of Government Efficiency when it was overseen by Elon Musk. The package to be voted on Thursday targets foreign aid programs and the Corporation for Public Broadcasting, which provides money for National Public Radio and the Public Broadcasting Service, as well as thousands of public radio and television stations around the country. Republicans are characterizing the spending as wasteful and unnecessary, but Democrats say the rescissions are hurting the United States' standing in the world. 'Cruelty is the point,' Democratic leader Hakeem Jeffries of New York said of the proposed spending cuts. The Trump administration is employing a tool rarely used in recent years that allows the president to transmit a request to Congress to cancel previously appropriated funds. That triggers a 45-day clock in which the funds are frozen pending congressional action. If Congress fails to act within that period, then the spending stands. The benefit for the administration of a formal rescissions request is that passage requires only a simple majority in the 100-member Senate instead of the 60 votes usually required to get spending bills through that chamber. So, if they stay united, Republicans will be able to pass the measure without any Democratic votes. The administration is likening the first rescissions package to a test case and says more could be on the way if Congress goes along. Republicans, sensitive to concerns that Trump's sweeping tax and immigration bill would increase future federal deficits, are anxious to demonstrate spending discipline, though the cuts in the package amount to just a sliver of the spending approved by Congress each year. They are betting the cuts prove popular with constituents who align with Trump's 'America first' ideology as well as those who view NPR and PBS as having a liberal bias. In all, the package contains 21 proposed rescissions. Approval would claw back about $900 million from $10 billion that Congress has approved for global health programs. That includes canceling $500 million for activities related to infectious diseases and child and maternal health and another $400 million to address the global HIV epidemic. The Trump administration is also looking to cancel $800 million, or a quarter of the amount Congress approved, for a program that provides emergency shelter, water and sanitation, and family reunification for those forced to flee their own country. About 45% of the savings sought by the White House would come from two programs designed to boost the economies, democratic institutions and civil societies in developing countries. The Republican president has also asked lawmakers to rescind nearly $1.1 billion from the Corporation for Public Broadcasting, which represents the full amount it's slated to receive during the next two budget years. About two-thirds of the money gets distributed to more than 1,500 locally owned public radio and television stations. Nearly half of those stations serve rural areas of the country. The association representing local public television stations warns that many of them would be forced to close if the Republican measure passes. Those stations provide emergency alerts, free educational programming and high school sports coverage and highlight hometown heroes. Advocacy groups that serve the world's poorest people are also sounding the alarm and urging lawmakers to vote no. 'We are already seeing women, children and families left without food, clean water and critical services after earlier aid cuts, and aid organizations can barely keep up with rising needs,' said Abby Maxman, president and CEO of Oxfam America, a poverty-fighting organization. Rep. Jim McGovern, D-Mass., said the foreign aid is a tool that prevents conflict and promotes stability but the measure before the House takes that tool away. 'These cuts will lead to the deaths of hundreds of thousands, devastating the most vulnerable in the world,' McGovern said. 'And at a time when China and Russia and Iran are working overtime to challenge American influence.' Republicans disparaged the foreign aid spending and sought to link it to programs they said DOGE had uncovered. Rep. Chip Roy, R-Texas, said taxpayer dollars had gone to such things as targeting climate change, promoting pottery classes and strengthening diversity, equity and inclusion programs. Other Republicans cited similar examples they said DOGE had revealed. 'Yet, my friends on the other side of the aisle would like you to believe, seriously, that if you don't use your taxpayer dollars to fund this absurd list of projects and thousands of others I didn't even list, that somehow people will die and our global standing in the world will crumble,' Roy said. 'Well, let's just reject this now.'
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
Innovation takes a backseat at small companies as tariffs become a full-time preoccupation
NEW YORK (AP) — Toy robots that teach children to code. Sneakers made in America. Mold-resistant kitchen gadgets. The three items are among new products that have gotten stuck in the pipeline due to President Donald Trump's unpredictable trade policies, according to the brand founders behind the stalled items. They say that instead of fostering U.S. innovation, Trump's tariffs are stifling it with extra costs and unexpected work. At Learning Resources in Vernon Hills, Illinois, Made Plus in Annapolis, Maryland, and Dorai Home in Salt Lake City, research and development have taken a backseat to recalculating budgets, negotiating with vendors and tracking shipments in the shifting tariff environment. 'If we don't have enough cash to cover just the restocks of the things that we know we need, do we want to take a risk on this new thing when we don't know how well it will sell yet?' Dorai Home founder Kelsey O'Callaghan said. O'Callaghan started the eco-friendly home goods company with a stone bath mat and now offers about 50 kitchen and bathroom accessories, which are made in China with a non-toxic material that dries quickly. New launches are critical to increasing sales and attracting customers, she said. As Trump increased the tariff on Chinese goods to 20% and as high as 145% before reducing the import tax rate to 30% for 90 days, Dorai Home postponed introducing new merchandise. O'Callaghan said she had to lay off the CEO as well as the head of product development, who helped the company jump on new trends. 'I haven't really put the time or the emphasis on (innovation) because I'm covering too many other people's roles,' she said. The company paused shipments from China in early April but resumed some on a staggered basis after the president's rate reduction. On Wednesday, Trump touted progress in U.S.-China trade talks. With details still sketchy and a deal not finalized, entrepreneurs interviewed by The Associated Press said they viewed the tariffs war as an ongoing threat. Tariffs and American innovation The potential stunting of innovation follows an economic slowdown during the coronavirus pandemic, when companies also had to put projects on hold. Some experts think the on-again-off again tariffs may have more enduring consequences because they rewire markets and upend business strategies. 'When executive attention shifts from innovation to regulatory compliance, the innovation pipeline suffers. Companies end up optimizing for the political landscape rather than technological advancement,' economists J. Bradford Jensen, a nonresident senior fellow at the Peterson Institute for International Economics, and Scott J. Wallsten, president of the Technology Policy Institute think tank, wrote in an April blog post. Trump has argued that curtailing foreign imports with tariffs would help revive the nation's diminished manufacturing base. Analysts and various trade groups have warned that fractured trade ties and supply chains may depress R&D activity of U.S. tech and health care companies that rely on international partnerships or foreign suppliers. Small companies, which often drive the innovations that create jobs and economic growth, already are under strain. With fewer people on staff and tighter budgets compared to large corporations, entrepreneurs say they are spending more time on cutting costs, suspending or arranging orders, and deciding how much of their tariff-related costs to charge customers. That means they're spending less time thinking of their next big ideas. Schylling Inc., a Massachusetts company that produces modern versions of Lava lamps, Sea-Monkeys, My Little Pony and other nostalgic toys, has its products made in China. As part of its strategy to account for tariffs, the company put a group of employees on temporary unpaid leave last month to reduce expenses. Marketing director Beth Muehlenkamp said she and other furloughed workers typically would have been planning products for the final months of 2026. But Schylling isn't focusing on designing new products given the unstable trade outlook. 'It's really hard to focus on innovation and creativity when you're consumed with this day-to-day of how we're just going to balance the books and deal with the changing rates,' Muehlenkamp said. An uneven product pipeline Even some companies that do their manufacturing in the U.S. are scaling back investments in new products. Made Plus, a Maryland company that makes athletic shoes at a small factory in the state capital, put a planned golf line on hold because two key components — a foam insole and the tread for the bottom of the shoe — currently are made in China, founder Alan Guyan said. The company customizes its shoes on demand and charges $145 to $200 a pair. The footwear is made from recycled plastic bottles with advanced knitting, 3D printing and computerized stitching techniques. It's looking into getting components from Vietnam instead of China. Embracing new technology is essential to restoring manufacturing capability in the U.S. and competing with Asia, Guyan said. But given ongoing trade frictions, he said he does not want to invest time or money evaluating the latest embroidery and knitting machines, which come from Germany, Italy, China and the U.S. 'We're just battening down the hatches a little bit and just hoping that there's enough influence in the community of footwear that it will somewhat change and get resolved and we can move forward,' he said of the tariff roller coaster. In contrast, many big companies are forging on. Google parent Alphabet confirmed late last month that it still planned to spend $75 billion on capital expenditures this year, with most of the money going toward artificial intelligence technology. What's next for R&D? Sonia Lapinsky, a managing director at consulting firm AlixPartners, has advised her clients to limit tariff discussions to a small group of executives and to keep their product creation cycles in motion. Businesses have an even greater imperative to come up with attention-grabbing innovations when consumers may be reluctant to open their wallets, she said. Yet smaller companies may struggle to wall off tariff discussions from the rest of the business. Monday Mornings The latest local business news and a lookahead to the coming week. Learning Resources CEO Rick Woldenberg said that roughly 25% to 30% of the 350 employees at the educational toy company's headquarters, including product developers, are working at least part-time on tariff-related tasks. The company usually develops 250 different products a year and expects to get half that many off the drawing board for 2026, Woldenberg said. While exploring factories in countries besides China, he said, Learning Resources is delaying the next generation of its interactive robots that help children develop computer programming skills through games and other activities. The family-run business and Woldenberg's other toy business, hand2Mind, are locked in a legal battle with the Trump administration. The jointly owned companies filed a lawsuit accusing the president of exceeding his authority by invoking an emergency powers law to impose tariffs. A federal judge ruled in favor of the two companies last month, and the administration has appealed the decision. Woldenberg said he's ready to take the case to the U.S. Supreme Court. 'It's a win at the Supreme Court that we need,' he said. 'And so until then, there will be no certainty. Even then, if the government is bound and determined to keep us in an uncertain situation, they'll be able to do that.'
Winnipeg Free Press
2 hours ago
- Winnipeg Free Press
Australia's defense minister downplays concerns over Pentagon review of multi-billion submarine deal
BANGKOK (AP) — Australia's defense minister dismissed concerns Thursday that a deal between the U.S., Australia and Britain to provide his country with nuclear-powered submarines could be in jeopardy, following a report that the Pentagon had ordered a review. Australian Defense Minister Richard Marles told Sky News Australia that he had known about the review of the deal 'for some time,' saying that it was a 'very natural step for the incoming administration to take.' He noted that the UK's government also reviewed the deal, the centerpiece of a three-way alliance known as AUKUS after it was elected, and that his own government had looked at it as part of its own review of Australia's entire defense posture. 'I think an incoming government having a look at this is something that they have a perfect right to do and we welcome it and we'll work with it,' he said. The deal, worth more than $200 billion, was signed between the three countries in 2021 under then President Joe Biden, designed to provide Australia, one of Washington's staunchest allies in the region, with greater maritime capabilities to counter China's increasingly strong navy. The deal also involves the U.S. selling several of its Virginia-class submarines to Australia to bridge the gap as the new submarines are being jointly built. In January, Australia made the first of six $500 million payments to the U.S. under the AUKUS deal, meant to bolster American submarine manufacturing. Marles met with U.S. Defense Secretary Pete Hegseth on the sidelines of a defense conference in Singapore less than two weeks ago, and told reporters afterward that he had come away with 'a sense of confidence about the way in which AUKUS is proceeding.' 'AUKUS is on track and we are meeting all the timelines that are associated with it,' he said. 'We are very optimistic.' Hegseth's address to the defense forum made multiple mentions of cooperation with Australia but no reference to AUKUS, however, though he did later mention the deal when he was taking questions. Hegseth did urge allies in the Indo-Pacific to increase their defense spending, and underscored the need for a 'strong, resolute and capable network of allies and partners' as the U.S. seeks to counter China.
